14M161: Abstracts: RA – Diagnosis, Manifestations, and Outcomes III: RA ILD (2248–2253)

Abstract Moderator(s)

• 

  Michael George, MD, MSc

  University of Pennsylvania
  Philadelphia, PA, United States

  Disclosure(s): AbbVie/Abbott: Consultant (Terminated, November 1, 2021); GlaxoSmithKlein(GSK): Grant/Research Support (Ongoing)
• 

  Janet Pope, MD, FRCPC, MPH

  University of Western Ontario
  London, ON, Canada

  Disclosure(s): AbbVie/Abbott: Consultant (Ongoing), Grant/Research Support (Ongoing); Actelion: Consultant (Ongoing); Amgen: Consultant (Ongoing); Bayer: Consultant (Ongoing); Boehringer Ingelheim: Advisor or Review Panel Member (Ongoing), Consultant (Ongoing), Speaker/Honoraria (includes speakers bureau, symposia, and expert witness) (Ongoing); Bristol-Myers Squibb(BMS): Consultant (Ongoing), Grant/Research Support (Ongoing); Eicos Sciences: Consultant (Ongoing); Eli Lilly: Consultant (Ongoing), Grant/Research Support (Ongoing); Emerald: Consultant (Ongoing); Gilead: Consultant (Ongoing); Janssen: Consultant (Ongoing); merk: Consultant (Ongoing), Grant/Research Support (Ongoing); Novartis: Consultant (Ongoing); Pfizer: Consultant (Ongoing); Roche: Consultant (Ongoing), Grant/Research Support (Ongoing); Sandoz: Consultant (Ongoing); Sanofi: Consultant (Ongoing); Seattle Genetics: Grant/Research Support (Ongoing); UCB: Consultant (Ongoing), Grant/Research Support (Ongoing), Speaker/Honoraria (includes speakers bureau, symposia, and expert witness) (Ongoing)

Oral abstract session.

Presentations:

• 4:30 PM – 4:40 PM Eastern Time

  Prevalence and Mortality of Interstitial Lung Abnormalities in Rheumatoid Arthritis and non-RA Comparators in a Multicenter Prospective Cohort
  

  Presenting Author: Gregory McDermott, MD – Brigham and Women's Hospital
• 4:40 PM – 4:45 PM Eastern Time

  Q&A
  
• 4:45 PM – 4:55 PM Eastern Time

  Impact of Interstitial Lung Disease on COVID-19 Severity Among Patients with Rheumatoid Arthritis: A Multicenter Comparative Study
  

  Presenting Author: Gabriel Figueroa-Parra, MD – Mayo Clinic
• 4:55 PM – 5:00 PM Eastern Time

  Q&A
  
• 5:00 PM – 5:10 PM Eastern Time

  Genetic and Environmental Risk Factors in Rheumatoid Arthritis-Associated Interstitial Lung Disease
  

  Presenting Author: Austin Wheeler, MD – University of Nebraska Medical Center
• 5:10 PM – 5:15 PM Eastern Time

  Q&A
  
• 5:15 PM – 5:25 PM Eastern Time

  Reduction in Rheumatoid Arthritis-Associated Interstitial Lung Disease Risk in Patients Treated with Tofacitinib
  

  Presenting Author: Matthew Baker, MD, MS – Stanford University
• 5:25 PM – 5:30 PM Eastern Time

  Q&A
  
• 5:30 PM – 5:40 PM Eastern Time

  Higher Matrix Metalloproteinase Levels Are Predictive of Incident Interstitial Lung Disease Among a Cohort of US Veterans with Rheumatoid Arthritis
  

  Presenting Author: Brent Luedders, MD – University of Nebraska Medical Center
• 5:40 PM – 5:45 PM Eastern Time

  Q&A
  
• 5:45 PM – 5:55 PM Eastern Time

  Sputum Cytokines Are Elevated in Rheumatoid Arthritis-Associated Interstitial Lung Disease
  

  Presenting Author: Timothy Wilson, MD – Thomas Jefferson University
• 5:55 PM – 6:00 PM Eastern Time

  Q&A